| Literature DB >> 31477125 |
Tara Purvis1, Sandy Middleton2,3, Louise E Craig2,3,4, Monique F Kilkenny5,6, Simeon Dale2,3, Kelvin Hill6,7, Catherine D'Este8,9, Dominique A Cadilhac5,4.
Abstract
BACKGROUND: In the Quality in Acute Stroke Care (QASC) trial undertaken in stroke units (SUs) located in New South Wales (NSW), Australia (2005-2010), facilitated implementation of a nurse-led care bundle to manage fever, hyperglycaemia and swallowing (FeSS protocols) reduced death and disability for patients with stroke. We aimed to determine subsequent adherence to the bundled FeSS processes (reflective of the protocols) between 2013 and 2017 in Australian hospitals, and examine whether changes in adherence to these processes varied based on previous participation in the QASC trial or subsequent statewide scale-up (QASCIP-Quality in Acute Stroke Care Implementation Project) and presence of an SU.Entities:
Keywords: Audit and feedback; Care bundles; Health services research; Quality improvement; Stroke
Mesh:
Year: 2019 PMID: 31477125 PMCID: PMC6721322 DOI: 10.1186/s13012-019-0934-y
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Comparison of processes collected in QASC, QASCIP and National Audits, with outline of FeSS processes included for analyses
| Processes included in the FeSS protocols | QASC | QASCIP | National Audits | Processes included in the current study and definition foranalysis | |||
|---|---|---|---|---|---|---|---|
| 2013 | 2015 | 2017 | |||||
| Fever | |||||||
| Temperature recorded at least four times on day 1, day 2 and day 3a | ✓ | ✓ | ✓ | × | × | ||
| Received paracetamol within 1 h of the first febrile event (recorded in first 72 h) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| F1 | Overall fever treatment | Patients without fever classified as receiving appropriate fever treatment | |||||
| Hyperglycaemia | |||||||
| Formal venous blood glucose level recorded in the ED | ✓ | ✓ | ✓ | × | × | ||
| Finger prick glucose recorded at least four times on day 1, day 2 and day 3a | ✓ | ✓ | ✓ | × | × | ||
| Insulin within 1 h if glucose > 10 mmol/Lb (recorded in the first 72 h) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| G1 | Overall hyperglycaemia treatment | Patients without high glucose classified as receiving appropriate hyperglycaemia treatment | |||||
| Swallow | |||||||
| S1 | Swallow screen or swallow assessment by speech pathologist within 24 h of admission | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| S2 | Swallow screen or assessment before food or drink | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| S3 | Swallow screen or assessment before oral medications | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| S4 | Overall swallow monitoring | Met all of S1, S2 and S3 (total cohort) | |||||
| S5 | Swallow assessment by speech pathologist if failed swallow screen | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ Those who did not fail swallow screen or did not receive the screen were classified as receiving appropriate swallow treatment |
| S6 | Overall swallow monitoring and treatment | If monitoring elements S1, S2, S3 and treatment element S5 all met | |||||
Composite outcome All fever, sugar and swallow elements | Met all of F1, G1 and S6 | ||||||
FeSS fever, sugar swallow; QASC Quality in Acute Stroke; QASCIP Quality in Acute Stroke Implementation Project; ED emergency department
aQuestion was asked individually for each of day 1, day 2 and day 3
bFinger prick glucose greater than 10 mmol/L (in QASC used 11 mmol/L, with changes reflecting recent updates in Australian guidelines)
Fig. 1Timeline of data collection and publications for QASC, QASCIP and National Audits
Organisational characteristics of hospitals participating in the National Audits
| Organisational characteristics of hospitals participating in the clinical audit | 2013 Audit, | 2015 Audit, | 2017 Audit, | |
|---|---|---|---|---|
| Dedicated stroke unit | 87 (70%) | 88 (79%) | 94 (80%) | 0.14 |
| Clinical care pathway for managing stroke | 94 (76%) | 93 (83%) | 99 (85%) | 0.18 |
| Regular stroke multidisciplinary team meetings | 115 (93%) | 106 (95%) | 107 (91%) | 0.64 |
| Agreed management (including assessment/monitoring) protocols for: | ||||
| Fever | 95 (77%) | 103 (92%) | 108 (92%) | < 0.001 |
| Hyperglycaemia | 100 (81%) | 104 (93%) | 106 (91%) | 0.009 |
| Swallow dysfunction | 106 (85%) | 107 (96%) | 114 (97%) | 0.001 |
aFrom chi-square test
Adherence to composite outcome and individual FeSS processes (2013–2017)
| FeSS monitoring and treatment processes | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| 2013, | 2015, | 2017, | 2013a–2015,OR (95% CI) | 2013a–2017,OR (95% CI) | 2015a–2017,OR (95% CI) | |
| Individual FeSS processes | ||||||
| Fever treatment | ||||||
| Paracetamol within 1 hb, c | 192 (36) | 186 (39) | 226 (49) | 1.1 (0.85, 1.5) |
|
|
| Overall fever treatmentb | 3099 (90) | 3800 (93) | 3952 (94) |
|
|
|
| Hyperglycaemia treatment | ||||||
| Insulin within 1 hb | 160 (25) | 204 (29) | 256 (38) | 1.3 (0.97, 1.6) |
|
|
| Overall hyperglycaemia treatmentb | 2947 (86) | 3579 (88) | 3781 (90) |
|
|
|
| Swallow monitoring | ||||||
| Swallow screen OR assessment within 24 h of hospital admission | 2310 (62) | 2618 (64) | 2884 (69) |
|
|
|
| Swallow screen or assessment before food or drink | 1875 (50) | 2222 (54) | 2600 (62) |
|
|
|
| Swallow screen or assessment before oral medications | 1687 (45) | 2047 (50) | 2420 (58) |
|
|
|
| Overall swallow monitoring | 1401 (37) | 1621 (40) | 2059 (49) |
|
|
|
| Swallow treatment | ||||||
| Assessed by speech pathologist if failed swallow screen | 562 (96) | 769 (97) | 826 (95) | 1.3 (0.74, 2.3) | 0.83 (0.50, 1.4) | 0.64 (0.38, 1.1) |
| Swallow treatmentd | 3716 (99) | 4061 (99) | 4149 (99) | 1.0 (0.58, 1.8) | 0.62 (0.38, 1.1) | 0.62 (0.38, 1.1) |
| Swallow monitoring and treatment | 1387 (37) | 1599 (39) | 2027 (48) |
|
|
|
| Composite outcome | ||||||
| All elements of fever, sugar, swallow dysfunction monitored and treated | 1024 (30)† | 1290 (32) | 1731 (41) |
|
|
|
Dependent variable in multivariable analyses is adherence to FeSS processes; independent variable is year, adjusted for correlation within hospital. Italicised results are significant
FeSS fever, sugar, swallow; OR odds ratio; CI confidence interval
aYear used as reference for multivariable analyses
bExcludes patients receiving palliative care in 2013
cIn 2015/2017, those contraindicated to and already receiving regular paracetamol included as ‘no’ in denominator
dAssessed by speech pathologist if failed swallow screen—those who passed or did not receive swallow screen were considered to have received appropriate treatment
Changes in adherence to composite outcome over time (2013–2017) by participation in QASC/QASCIP and the presence of a stroke unit
| 2015 vs 2013a | 2017 vs 2015a | 2017 vs 2013a | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| Participation in QASC/QASCIP | ||||||
| Participatedc | 1.2 (0.95, 1.6) | 0.4 | 1.7 (1.4, 2.0) | 0.4 | 2.1 (1.7, 2.7) | 0.03 |
| Not participatedc | 1.1 (0.93, 1.2) | 1.5 (1.4, 1.7) | 1.6 (1.4, 1.8) | |||
| Presence of a stroke unit | ||||||
| Yes | 1.0 (0.93, 1.2) | 0.051 | 1.7 (1.5, 1.8) | 0.09 | 1.7 (1.5, 1.9) | 0.6 |
| No | 1.4 (1.04, 1.9) | 1.4 (1.0, 1.8) | 1.9 (1.4, 2.6) | |||
Dependent variable is adherence to composite outcome measure; independent variables include interaction term between year/participation QASC/QASCIP or year/stroke unit presence, adjusted for correlation within hospital. OR Odds Ratio, CI Confidence Interval
aReference year
bFor the interaction term
cParticipated in QASC or QASCIP
Fig. 2Change in adherence to the composite outcome in 2013 compared to 2017: by previous participation in QASC/QASCIP
Fig. 3Change in adherence to the composite outcome in 2013 compared to 2017: by presence of a stroke unit